Brodehl Andreas, Gaertner-Rommel Anna, Milting Hendrik
Erich and Hanna Klessmann Institute for Cardiovascular Research & Development, Heart and Diabetes Centre NRW, Ruhr-University Bochum, Georgstrasse 11, 32545, Bad Oeynhausen, Germany.
Biophys Rev. 2018 Aug;10(4):983-1006. doi: 10.1007/s12551-018-0429-0. Epub 2018 Jun 20.
Increasing usage of next-generation sequencing techniques pushed during the last decade cardiogenetic diagnostics leading to the identification of a huge number of genetic variants in about 170 genes associated with cardiomyopathies, channelopathies, or syndromes with cardiac involvement. Because of the biochemical and cellular complexity, it is challenging to understand the clinical meaning or even the relevant pathomechanisms of the majority of genetic sequence variants. However, detailed knowledge about the associated molecular pathomechanism is essential for the development of efficient therapeutic strategies in future and genetic counseling. Mutations in DES, encoding the muscle-specific intermediate filament protein desmin, have been identified in different kinds of cardiac and skeletal myopathies. Here, we review the functions of desmin in health and disease with a focus on cardiomyopathies. In addition, we will summarize the genetic and clinical literature about DES mutations and will explain relevant cell and animal models. Moreover, we discuss upcoming perspectives and consequences of novel experimental approaches like genome editing technology, which might open a novel research field contributing to the development of efficient and mutation-specific treatment options.
在过去十年中,新一代测序技术的使用日益增加,推动了心脏遗传学诊断的发展,从而在约170个与心肌病、离子通道病或累及心脏的综合征相关的基因中鉴定出大量基因变异。由于生物化学和细胞层面的复杂性,理解大多数基因序列变异的临床意义乃至相关发病机制具有挑战性。然而,关于相关分子发病机制的详细知识对于未来高效治疗策略的开发和遗传咨询至关重要。编码肌肉特异性中间丝蛋白结蛋白的DES基因突变已在不同类型的心脏和骨骼肌病中被发现。在此,我们综述结蛋白在健康和疾病中的功能,重点关注心肌病。此外,我们将总结关于DES突变的遗传学和临床文献,并解释相关的细胞和动物模型。此外,我们还将讨论基因组编辑技术等新型实验方法的未来前景和影响,这些方法可能会开辟一个新的研究领域,有助于开发高效且针对突变的治疗方案。